SOPHiA GENETICS (NASDAQ:SOPH) Insider Zhenyu Xu Sells 4,000 Shares of Company Stock

Posted by Scott Moore on Oct 14th, 2026

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $7.18, for a total transaction of $28,720.00. Following the transaction, the insider owned 541,493 shares in the company, valued at $3,887,919.74. The trade was a 0.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

On Monday, October 5th, Zhenyu Xu sold 7,394 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.12, for a total transaction of $60,039.28.
On Thursday, August 27th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.91, for a total value of $89,100.00.
On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $30,080.00.
On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.29, for a total value of $123,930.00.
On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.00, for a total value of $21,000.00.
On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $69,200.00.

SOPHiA GENETICS Stock Down 0.4%

Shares of NASDAQ SOPH traded down $0.03 on Wednesday, hitting $7.06. The company had a trading volume of 376,763 shares, compared to its average volume of 310,258. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a 12-month low of $3.75 and a 12-month high of $8.98. The firm has a market capitalization of $592.26 million, a P/E ratio of -6.14 and a beta of 0.95. The business has a 50 day moving average of $7.95 and a two-hundred day moving average of $6.20.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS during the second quarter worth about $9,809,000. Hodges Capital Management Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at about $2,157,000. Sei Investments Co. purchased a new position in SOPHiA GENETICS in the first quarter valued at about $1,772,000. Maven Securities LTD purchased a new position in SOPHiA GENETICS in the second quarter valued at about $866,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in SOPHiA GENETICS during the 2nd quarter valued at approximately $567,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. BTIG Research lifted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of SOPHiA GENETICS in a research report on Monday. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and a consensus price target of $10.00.

Check Out Our Latest Report on SOPHiA GENETICS

SOPHiA GENETICS Company Profile

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.